Compare YDESW & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YDESW | WGSWW |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | 1000 |
| Industry | | Retail: Computer Software & Peripheral Equipment |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | YDESW | WGSWW |
|---|---|---|
| Price | $1.15 | $0.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 36.6K |
| Earning Date | N/A | 02-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $305,450,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 50.79 |
| 52 Week Low | N/A | $0.17 |
| 52 Week High | N/A | $0.21 |
| Indicator | YDESW | WGSWW |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 41.01 |
| Support Level | N/A | $0.04 |
| Resistance Level | N/A | $0.06 |
| Average True Range (ATR) | 0.00 | 0.01 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 38.01 |
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.